AU2001252458A1 - Molecular antigen arrays and vaccines - Google Patents
Molecular antigen arrays and vaccinesInfo
- Publication number
- AU2001252458A1 AU2001252458A1 AU2001252458A AU5245801A AU2001252458A1 AU 2001252458 A1 AU2001252458 A1 AU 2001252458A1 AU 2001252458 A AU2001252458 A AU 2001252458A AU 5245801 A AU5245801 A AU 5245801A AU 2001252458 A1 AU2001252458 A1 AU 2001252458A1
- Authority
- AU
- Australia
- Prior art keywords
- vaccines
- antigen arrays
- molecular antigen
- molecular
- arrays
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 238000003491 array Methods 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/807—Hapten conjugated with peptide or protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20234100P | 2000-05-05 | 2000-05-05 | |
US60/202,341 | 2000-05-05 | ||
PCT/IB2001/000741 WO2001085208A2 (en) | 2000-05-05 | 2001-05-02 | Molecular antigen arrays and vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001252458A1 true AU2001252458A1 (en) | 2001-11-20 |
Family
ID=22749482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001252458A Abandoned AU2001252458A1 (en) | 2000-05-05 | 2001-05-02 | Molecular antigen arrays and vaccines |
Country Status (5)
Country | Link |
---|---|
US (2) | US6964769B2 (en) |
EP (1) | EP1278542A2 (en) |
AU (1) | AU2001252458A1 (en) |
CA (1) | CA2407897A1 (en) |
WO (1) | WO2001085208A2 (en) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ512456A (en) * | 1998-11-30 | 2003-10-31 | Cytos Biotechnology Ag | Ordered molecular presentation of antigens |
US20030138769A1 (en) * | 2000-08-16 | 2003-07-24 | Birkett Ashley J. | Immunogenic HBc chimer particles having enhanced stability |
US7128911B2 (en) | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
US7094409B2 (en) | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
US7320793B2 (en) * | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
WO2002072853A1 (en) * | 2001-03-12 | 2002-09-19 | Ark Therapeutics Limited | Avidin-pseudotyped viral vectors and their use |
US20040146524A1 (en) * | 2002-02-21 | 2004-07-29 | Katelynne Lyons | Stabilized immunogenic HBc chimer particles |
AU2002339224B2 (en) | 2001-09-14 | 2008-10-09 | Kuros Us Llc | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
CA2462857C (en) * | 2001-10-05 | 2012-01-24 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
BR0213117A (en) | 2001-10-05 | 2004-09-21 | Cytos Biotechnology Ag | Angiotensin-vehicle peptide conjugates and their uses |
PL369685A1 (en) * | 2001-11-07 | 2005-05-02 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
AU2003205623A1 (en) * | 2002-01-18 | 2003-07-30 | Cytos Biotechnology Ag | Prion protein carrier-conjugates |
US7351413B2 (en) | 2002-02-21 | 2008-04-01 | Lorantis, Limited | Stabilized HBc chimer particles as immunogens for chronic hepatitis |
AU2003237528A1 (en) * | 2002-06-07 | 2003-12-22 | Kentucky Bioprocessing, Llc | Flexible vaccine assembly and vaccine delivery platform |
CN1662253A (en) * | 2002-06-20 | 2005-08-31 | 赛托斯生物技术公司 | Packaged virus-like particles for use as adjuvants: method of preparation and use |
AU2003246690B2 (en) | 2002-07-17 | 2010-03-11 | Cytos Biotechnology Ag | Molecular antigen arrays using a virus like particle derived from the AP205 coat protein |
US6932971B2 (en) | 2002-07-18 | 2005-08-23 | Cytos Biotechnology Ag | Hapten-carrier conjugates and uses thereof |
CN1665565A (en) * | 2002-07-19 | 2005-09-07 | 赛托斯生物技术公司 | GHRELIN-carrier conjugates |
CA2492930C (en) | 2002-07-19 | 2013-01-08 | Cytos Biotechnology Ag | Vaccine compositions containing amyloid beta1-6 antigen arrays |
WO2004080403A2 (en) * | 2003-03-07 | 2004-09-23 | Merck & Co. Inc. | Influenza virus vaccine |
KR20050115913A (en) | 2003-03-26 | 2005-12-08 | 사이토스 바이오테크놀로지 아게 | Melan-a peptide analogue-virus-like-particle conjugates |
US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
ES2217967B1 (en) * | 2003-03-31 | 2006-01-01 | Consejo Sup. Investig. Cientificas | PROCEDURE FOR THE PRODUCTION OF EMPTY VIRAL PARTICLES (VLPS) OF THE INFECTIOUS BURSITIS INDUCTOR VIRUS (IBDV), COMPOSITIONS NEEDED FOR ITS POSITIONING AND ITS USE IN THE DEVELOPMENT OF VACCINES AGAINST IBDV. |
TWI224273B (en) * | 2003-04-10 | 2004-11-21 | Inventec Corp | Switching system for operation priority of I/O unit and method thereof |
KR20060128924A (en) * | 2004-01-20 | 2006-12-14 | 사이토스 바이오테크놀로지 아게 | Ghrelin-carrier conjugates |
ES2307345B1 (en) * | 2004-01-21 | 2009-11-13 | Consejo Sup. Investig. Cientificas | CHEMICAL EMPTY CAPSIDES OF THE VIRUS CAUSING THE INFECTIOUS BURSITIS DISEASE (IBDV), ITS PROCEDURE FOR OBTAINING AND APPLICATIONS. |
ES2307346B1 (en) * | 2004-01-21 | 2009-11-13 | Consejo Sup. Investig. Cientificas | EMPTY CAPSIDES (VLPS (-VP4)) OF THE VIRUS CAUSING THE INFECTIOUS BURSITIS DISEASE (IBDV), ITS PROCESSING PROCEDURE AND APPLICATIONS. |
AR044603A1 (en) | 2004-06-03 | 2005-09-21 | Consejo Nac Invest Cient Tec | ISOLATED CHEMICAL PROTEINS OF LUMAZINE SYNTHEASE MODIFIED FOR THE MULTIPLE PRESENTATION OF MOLECULES AND ITS APPLICATIONS |
KR20070059207A (en) * | 2004-10-05 | 2007-06-11 | 사이토스 바이오테크놀로지 아게 | Vlp-antigen conjugates and their uses as vaccines |
CA2580919A1 (en) | 2004-10-25 | 2006-05-04 | Cytos Biotechnology Ag | Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof |
GB0424563D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
AU2005315658A1 (en) * | 2004-12-13 | 2006-06-22 | Cytos Biotechnology Ag | IL-15 antigen arrays and uses thereof |
WO2006097530A2 (en) * | 2005-03-18 | 2006-09-21 | Cytos Biotechnology Ag | Cat allergen fusion proteins and uses thereof |
EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
ES2310062B1 (en) * | 2005-07-15 | 2009-11-13 | Bionostra, S.L. | PSEUDOVIRAL PARTICLES CHEMICAL EMPTY DERIVED FROM VIRUS CAUSING INFECTIOUS BURSITIS DISEASE (IBDV), PROCEDURE OF OBTAINING AND APPLICATIONS. |
ZA200802225B (en) | 2005-09-28 | 2009-10-28 | Cytos Biotechnology Ag | Interleukin-1 conjugates and uses thereof |
US20070184068A1 (en) | 2005-12-14 | 2007-08-09 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
CA2655108C (en) | 2006-06-12 | 2019-05-07 | Cytos Biotechnology Ag | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
US20080015145A1 (en) * | 2006-07-11 | 2008-01-17 | Maria Gyongyossy-Issa | Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions |
WO2008100609A1 (en) * | 2007-02-16 | 2008-08-21 | The Salk Institute For Biological Studies | A novel antitoxin and vaccine platform based on nodavirus vlps |
MX337723B (en) | 2008-12-09 | 2016-03-15 | Pfizer Vaccines Llc | IgE CH3 PEPTIDE VACCINE. |
MX2012001194A (en) | 2009-07-30 | 2012-03-07 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof. |
CA2770075C (en) * | 2009-08-07 | 2021-08-24 | Perrine Martin | Composition for treating hbv infection |
ES2641892T3 (en) * | 2009-08-26 | 2017-11-14 | Selecta Biosciences, Inc. | Compositions that induce the help of T cells |
EP2865752A1 (en) | 2009-09-03 | 2015-04-29 | Pfizer Vaccines LLC | PCSK9 vaccine |
CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
WO2011150258A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
EP2575868A1 (en) | 2010-06-07 | 2013-04-10 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
MX343830B (en) | 2011-02-11 | 2016-11-24 | Univ Pennsylvania | Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same. |
US9238679B2 (en) | 2011-02-11 | 2016-01-19 | The Trustees Of The University Of Pennslyvania | Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same |
EP2680883B1 (en) | 2011-03-02 | 2018-09-05 | Pfizer Inc | Pcsk9 vaccine |
US9265815B2 (en) | 2011-04-29 | 2016-02-23 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers |
PL2691530T3 (en) | 2011-06-10 | 2019-02-28 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
US20130028857A1 (en) | 2011-07-29 | 2013-01-31 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents |
EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
US9572815B2 (en) | 2013-03-15 | 2017-02-21 | St. Jude Children's Research Hospital | Methods and compositions of p27KIP1 transcriptional modulators |
JP7028556B2 (en) | 2013-05-03 | 2022-03-02 | セレクタ バイオサイエンシーズ インコーポレーテッド | Delivery of immunosuppressive agents with antigens for specific pharmacodynamic efficacy and induction of immune tolerance |
CN112933218A (en) | 2013-06-04 | 2021-06-11 | 西莱克塔生物科技公司 | Repeated administration of non-immunosuppressive antigen-specific immunotherapeutics |
EP3027205A4 (en) | 2013-07-28 | 2017-07-19 | Qantu Therapeutics, Inc. | Vaccine formulations that induce a th2 immune response |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
CA2924733C (en) | 2013-09-29 | 2018-02-27 | St. Jude Children's Research Hospital, Inc. | Aryl substituted aminomethyl spectinomycin analogs as antibacterial agents |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3104877B1 (en) | 2014-02-11 | 2020-01-22 | The USA, as represented by The Secretary, Department of Health and Human Services | Pcsk9 vaccine and methods of using the same |
EP3148566B1 (en) * | 2014-06-02 | 2024-04-03 | ISA Pharmaceuticals B.V. | Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection |
CA2953507A1 (en) | 2014-06-25 | 2015-12-30 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
MX2017002933A (en) | 2014-09-07 | 2017-05-30 | Selecta Biosciences Inc | Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses. |
MA40824A (en) | 2014-10-22 | 2017-08-29 | Saiba Gmbh | MODIFIED VIRUS TYPE CMV PARTICLES |
EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3786164A1 (en) | 2015-06-18 | 2021-03-03 | Ting Therapeutics LLC | Methods and compositions for the prevention and treatment of hearing loss |
WO2017096262A1 (en) | 2015-12-04 | 2017-06-08 | Jomoco, Corp. | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates |
WO2017179025A1 (en) | 2016-04-15 | 2017-10-19 | Alk-Abelló A/S | Epitope polypeptides of ragweed pollen allergens |
CN116077439A (en) | 2016-04-29 | 2023-05-09 | 西奈山伊坎医学院 | Targeting the innate immune system to induce long-term tolerance and address macrophage accumulation in atherosclerosis |
WO2018064215A1 (en) | 2016-09-27 | 2018-04-05 | Selecta Biosciences, Inc. | Recombinant immunotoxins for use in the treatment of cancer |
AU2018205496A1 (en) | 2017-01-07 | 2019-07-25 | Selecta Biosciences, Inc. | Patterned dosing of immunosuppressants coupled to synthetic nanocarriers |
WO2018169811A1 (en) | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
CN111542336A (en) | 2017-10-13 | 2020-08-14 | 西莱克塔生物科技公司 | Methods and compositions for attenuating antiviral transfer vector IGM response |
US11633471B2 (en) | 2018-03-06 | 2023-04-25 | Unm Rainforest Innovations | Compositions and methods for reducing serum triglycerides |
EP3823676A1 (en) | 2018-07-16 | 2021-05-26 | Selecta Biosciences, Inc. | Methods and compositions of mma constructs and vectors |
CN112771070A (en) | 2018-07-16 | 2021-05-07 | 西莱克塔生物科技公司 | Methods and compositions of OTC constructs and vectors |
US20200360453A1 (en) | 2019-04-28 | 2020-11-19 | Selecta Biosciences, Inc. | Methods for treatment of subjects with preexisting immunity to viral transfer vectors |
WO2020243261A1 (en) | 2019-05-28 | 2020-12-03 | Selecta Biosciences, Inc. | Methods and compositions for attenuated anti-viral transfer vector immune response |
CN115279905A (en) | 2019-10-23 | 2022-11-01 | 里珍纳龙药品有限公司 | Synthetic RIG-I like receptor agonists |
WO2022150335A1 (en) | 2021-01-05 | 2022-07-14 | Selecta Biosciences, Inc. | Viral vector dosing protocols |
BR112023018950A2 (en) | 2021-03-19 | 2024-02-27 | Icahn School Med Mount Sinai | COMPOUND, NANOBIOLOGICAL AND PHARMACEUTICAL COMPOSITIONS, METHODS FOR TREATING A CELL PROLIFERATION DISORDER, FOR TREATING SEPSIS AND FOR ACTIVATING A NOD2 RECEPTOR, PROCESS FOR MANUFACTURING A NANOBIOLOGICAL COMPOSITION AND KIT |
WO2022217095A1 (en) | 2021-04-09 | 2022-10-13 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance |
WO2023064350A1 (en) | 2021-10-12 | 2023-04-20 | Selecta Biosciences, Inc. | Viral vector dosing protocols |
WO2023064367A1 (en) | 2021-10-12 | 2023-04-20 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
CA3237037A1 (en) | 2021-11-14 | 2023-05-19 | Cartesian Therapeutics, Inc. | Multiple dosing with viral vectors |
US20230263906A1 (en) | 2022-01-10 | 2023-08-24 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing |
US20230357437A1 (en) | 2022-03-09 | 2023-11-09 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
WO2023172628A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing |
WO2023183568A1 (en) | 2022-03-25 | 2023-09-28 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents |
WO2023196566A1 (en) | 2022-04-08 | 2023-10-12 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5204096A (en) * | 1984-03-07 | 1993-04-20 | New York Blood Center, Inc. | Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers |
US4722840A (en) | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US6103243A (en) * | 1985-05-15 | 2000-08-15 | Biotechnology Australia Pty, Ltd | Oral vaccines |
US6086880A (en) * | 1985-12-26 | 2000-07-11 | The University Of Saskatchewan | Rotavirus peptide compositions and methods of use |
CA1319101C (en) | 1986-09-03 | 1993-06-15 | Marta Iris Sabara | Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules |
US5374426A (en) | 1986-09-03 | 1994-12-20 | University Of Saskatchewan | Rotavirus nucleocapsid protein VP6 in vaccine compositions |
US5554372A (en) * | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
DE3750176T2 (en) | 1986-09-22 | 1994-10-13 | Univ Emory | VACCINE AND PRODUCTION METHOD. |
US5143726A (en) | 1986-12-09 | 1992-09-01 | The Scripps Research Institute | T cell epitopes of the hepatitis B virus nucleocapsid protein |
GB8903313D0 (en) | 1989-02-14 | 1989-04-05 | Wellcome Found | Conjugates |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
EP0425082B1 (en) | 1989-09-04 | 1995-04-26 | Evans Medical Limited | Bordetella vaccines |
US5178882A (en) | 1990-06-22 | 1993-01-12 | The Regents Of The University Of California | Viral decoy vaccine |
US5334394A (en) | 1990-06-22 | 1994-08-02 | The Regents Of The University Of California | Human immunodeficiency virus decoy |
SE9003978D0 (en) | 1990-12-13 | 1990-12-13 | Henrik Garoff | DNA EXPRESSION SYSTEM BASED ON A VIRUS REPLICATION |
EP0563091A1 (en) | 1990-12-20 | 1993-10-06 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccines based on hepatitis b surface antigen |
GB9114003D0 (en) | 1991-06-28 | 1991-08-14 | Mastico Robert A | Chimaeric protein |
ZA934199B (en) * | 1992-06-18 | 1994-01-10 | Akzo Nv | Carrier system against gnrh |
US6004763A (en) | 1992-09-11 | 1999-12-21 | Institut Pasteur | Antigen-carrying microparticles and their use in the induction of humoral or cellular responses |
FR2695563B1 (en) | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticles carrying antigens and their use for the induction of humoral or cellular responses. |
CA2153391C (en) | 1993-01-11 | 2000-08-15 | Kenneth Rock | Inducing cytotoxic t lymphocyte responses |
WO1994017813A1 (en) | 1993-02-08 | 1994-08-18 | Paravax, Inc. | Defective sindbis virus vectors that express toxoplasma gondii p30 antigens |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
AT402898B (en) | 1994-08-08 | 1997-09-25 | Int Centre Genetic Eng & Bio | MOLECULAR PRESENTATION SYSTEM |
US5935821A (en) | 1995-01-17 | 1999-08-10 | Board Of Trustees Of The University Of Kentucky | Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
WO1996030523A2 (en) | 1995-03-31 | 1996-10-03 | Hans Wolf | Antigen presentation system based on retrovirus-like particles |
US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
DK0885244T4 (en) | 1996-03-01 | 2008-06-16 | Novartis Ag | Peptide immunogens for vaccination against and for the treatment of allergies |
US5770380A (en) | 1996-09-13 | 1998-06-23 | University Of Pittsburgh | Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold |
GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
DK1005368T3 (en) * | 1997-03-10 | 2010-01-04 | Ottawa Hospital Res Inst | Use of nucleic acids containing non-methylated CpG dinucleotide in combination with alum as adjuvants |
CA2297786C (en) | 1997-08-05 | 2011-06-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie | New immunoprotective influenza antigen and its use in vaccination |
US6169175B1 (en) | 1997-08-06 | 2001-01-02 | Centers For Disease Control And Prevention | Preparation and use of recombinant influenza A virus M2 construct vaccines |
US6054312A (en) | 1997-08-29 | 2000-04-25 | Selective Genetics, Inc. | Receptor-mediated gene delivery using bacteriophage vectors |
CN100387622C (en) * | 1998-02-12 | 2008-05-14 | 免疫合成物公司 | Strategically modified hepatitis b core proteins and their derivatives |
JP2002509729A (en) | 1998-03-27 | 2002-04-02 | サイトス バイオテクノロジー アーゲー | Inducible alphavirus gene expression system |
US5990085A (en) | 1998-05-04 | 1999-11-23 | Michigan State University | Inhibin-HBc fusion protein |
TWI227241B (en) | 1998-06-20 | 2005-02-01 | United Biomedical Inc | IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate |
NZ512456A (en) * | 1998-11-30 | 2003-10-31 | Cytos Biotechnology Ag | Ordered molecular presentation of antigens |
NZ513680A (en) | 1999-02-25 | 2001-09-28 | Peptide Therapeutics Ltd | Epitodes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of IgE, antagonists thereof, and their therapeutic uses |
AU2003246690B2 (en) | 2002-07-17 | 2010-03-11 | Cytos Biotechnology Ag | Molecular antigen arrays using a virus like particle derived from the AP205 coat protein |
US6932971B2 (en) | 2002-07-18 | 2005-08-23 | Cytos Biotechnology Ag | Hapten-carrier conjugates and uses thereof |
CN1665565A (en) | 2002-07-19 | 2005-09-07 | 赛托斯生物技术公司 | GHRELIN-carrier conjugates |
-
2001
- 2001-05-02 CA CA002407897A patent/CA2407897A1/en not_active Abandoned
- 2001-05-02 WO PCT/IB2001/000741 patent/WO2001085208A2/en active Application Filing
- 2001-05-02 EP EP01925778A patent/EP1278542A2/en not_active Withdrawn
- 2001-05-02 AU AU2001252458A patent/AU2001252458A1/en not_active Abandoned
- 2001-05-04 US US09/848,616 patent/US6964769B2/en not_active Expired - Fee Related
-
2005
- 2005-11-10 US US11/270,774 patent/US20060222652A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20030054010A1 (en) | 2003-03-20 |
CA2407897A1 (en) | 2001-11-15 |
WO2001085208A2 (en) | 2001-11-15 |
US6964769B2 (en) | 2005-11-15 |
WO2001085208A8 (en) | 2002-09-19 |
EP1278542A2 (en) | 2003-01-29 |
WO2001085208A3 (en) | 2002-05-23 |
US20060222652A1 (en) | 2006-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001252458A1 (en) | Molecular antigen arrays and vaccines | |
AU2002225681A1 (en) | Yeast-dentritic cell vaccines and uses thereof | |
AU3760100A (en) | Immunostimulatory nucleic acids and antigens | |
AU2001245504A1 (en) | Everting staple devices and methods | |
CY2009014I1 (en) | VACCINE AGAINST BACTERIAL ANTIGENS | |
IL151853A (en) | Multivalent antibodies and uses thereof | |
AU1951201A (en) | Peptide antigens | |
AU2001290860A1 (en) | Spas-1 cancer antigen | |
AU2002211717A1 (en) | Stresscopins and their uses | |
AU2001271976A1 (en) | Microspheres and adjuvants for dna vaccine delivery | |
AU2002243392A1 (en) | Immunogenic proteoliposomes, and uses thereof | |
AU2001248172A1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
AU2002214150A1 (en) | Canine and feline tumour-associated antigen 5t4 | |
AU2001248171A1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
AU2001248176A1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
AU2002243314A1 (en) | Immunogenic cancer peptides and uses thereof | |
AU2001295185A1 (en) | Multiplexing-interleaving and demultiplexing-deinterleaving | |
AU7308200A (en) | Novel hev antigenic peptide and methods | |
AU2001259077A1 (en) | Immunomodulatory methods using carbohydrate antigens | |
AU2001295582A1 (en) | Tumour-related antigens | |
AU3283500A (en) | Tumor-associated antigen | |
AU2001272373A1 (en) | Cgtase and dna sequence encoding same | |
AU2001261317A1 (en) | Immunostimulant compositions and associated methods | |
AU2001261534A1 (en) | The meca-79 antigen and related methods | |
AU2001249820A1 (en) | Methods and systems for molecular fingerprinting |